Seroprevalence and demographic determinants of human T-lymphotropic virus Type 1 and 2 infections among first-time blood donors-United States, 2000-2009

Journal of Infectious Diseases

Volumn 209, Issue 4, 2014, Pages 523-531

  Chang, Yun Brenda ^a,b   Kaidarova, Zhanna ^b   Hindes, Daniel ^b   Bravo, Marjorie ^e   Kiely, Nancy ^e   Kamel, Hany ^e   Dubay, Denise ^c   Hoose, Barbara ^e   Murphy, Edward L ^b,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^c Blood Centers of the Pacific   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Blood Systems Incorporated   (United States)

Author keywords

blood donors; demographic determinants; HTLV 1; HTLV 2; Human T lymphotropic virus; prevalence; United States

Indexed keywords

BLOOD DONORS; DEMOGRAPHIC DETERMINANTS; HTLV-1; HTLV-2; HUMAN T-LYMPHOTROPIC VIRUS; PREVALENCE; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; BLOOD DONORS; CHI-SQUARE DISTRIBUTION; FEMALE; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEROEPIDEMIOLOGIC STUDIES; UNITED STATES;

EID: 84893218221     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit497     Document Type: Conference Paper

References (34)

1. Murphy EL, Biswas HH. Human T-cell lymphotrophic virus types I and II. Chapter 168. In: Mandell G, Bennett J, eds. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingston/Elsevier, 2009: 2303-22.
2. Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 2012; 84:327-35.
3. Cassar O, Charavay F, Bassot S, et al. Divergent KSHV/HHV-8 subtype D strains in New Caledonia and Solomon Islands, Melanesia. J Clin Virol 2012; 53:214-8.
4. Roucoux DF, Murphy EL. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev 2004; 6:144-54.
5. Khabbaz RF, Onorato IM, Cannon RO, et al. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992; 326:375-80.
6. Hino S, Katamine S, Miyamoto T, et al. Association between maternal antibodies to the external envelope glycoprotein and vertical transmission of human T-lymphotropic virus type I. Maternal anti-env antibodies correlate with protection in non-breast-fed children. J Clin Invest 1995; 95:2920-5.
7. Wiktor SZ, Pate EJ, Murphy EL, et al. Mother-to-child transmission of human T-cell lymphotropic virus type I (HTLV-I) in Jamaica: association with antibodies to envelope glycoprotein (gp46) epitopes. J Acquir Immune Defic Syndr 1993; 6:1162-7.
8. Roucoux DF, Wang B, Smith D, et al. A prospective study of sexual transmission of human T lymphotropic virus (HTLV)-I and HTLV-II. J Infect Dis 2005; 191:1490-7.
9. Iga M, Okayama A, Stuver S, et al. Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses. J Infect Dis 2002; 185:691-5.
10. Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992; 51:886-91.
11. Murphy EL, Figueroa JP, Gibbs WN, et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1989; 111:555-60.
12. Chen YM, Yu PS, Lin CC, Jen I. Surveys of HIV-1, HTLV-I, and other sexually transmitted diseases in female sex workers in Taipei City, Taiwan, from 1993 to 1996. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:299-303.
13. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984; 46:245-53.
14. Donegan E, Lee H, Operskalski EA, et al. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 1994; 34: 478-83.
15. Catalan-Soares B, Carneiro-Proietti AB, Proietti FA. Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publica 2005; 21: 926-31.
16. Courouce AM, Pillonel J, Lemaire JM, Maniez M, Brunet JB. Seroepidemiology of HTLV-I/II in universal screening of blood donations in France. Aids 1993; 7:841-7.
17. Laperche S, Worms B, Pillonel J. Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang 2009; 96:104-10.
18. Murphy EL, Watanabe K, Nass CC, Ownby H, Williams A, Nemo G. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis 1999; 180:1777-83.
19. Dodd RY, Notari EPt, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975-9.
20. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284:229-35.
21. Gallo D, Penning LM, Hanson CV. Detection and differentiation of antibodies to human T-cell lymphotropic virus types I and II by the immunofluorescence method. J Clin Microbiol 1991; 29:2345-7.
22. Feigal E, Murphy E, Vranizan K, et al. Human T cell lymphotropic virus type I and II in intravenous drug users in San Francisco: risk factors associated with seropositivity. J Infect Dis 1991; 164:36-42.
23. Kaplan JE, Khabbaz RF, Murphy EL, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. The Retrovirus Epidemiology Donor Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:193-201.
24. Greenblatt J. Unpublished data from the 1991-92 Household Survey on Drug Abuse. Rockville, MD: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, US Dept. of Health and Human Services, 1994.
25. Lee HH, Swanson P, Rosenblatt JD, et al. Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet 1991; 337:1435-9.
26. Williams AE, Fang CT, Slamon DJ, et al. Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors. Science 1988; 240:643-6.
27. Schreiber GB, Murphy EL, Horton JA, et al. Risk factors for human Tcell lymphotropic virus types I and II (HTLV-I and-II) in blood donors: the Retrovirus Epidemiology Donor Study. NHLBI Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:263-71.
28. Oguma S, Imamura Y, Kusumoto Y, et al. Stable human T-lymphotropic virus type I carrier rates for 7 years among a teenaged blood donor cohort of 1986 in Kumamoto, Japan. Leuk Res 1995; 19:567-71.
29. Fukushima Y, Takahashi H, Hall WW, et al. Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in south Vietnam. AIDS Res Hum Retroviruses 1995; 11:637-45.
30. Liu H, Leung P, Glynn S, Murphy EL. Human T-lymphotropic virus type II RFLP subtypes a0 and b4/b5 are associated with different demographic and geographic characteristics in the United States. Virology 2001; 279:90-6.
31. Murphy EL, Figueroa JP, Gibs WN, et al. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica: I. Demographic determinants. Am J Epid 1991; 133:1114-24.
32. Carneiro-Proietti AB, Sabino EC, Leão S, et al. Human T-lymphotropic virus type 1 and type 2 seroprevalence, incidence, and residual transfusion risk among blood donors in Brazil during 2007-2009. AIDS Res Hum Retroviruses. 2012; 28:1265-72.
33. Vrielink H, Reesink HW. HTLV-I/II prevalence in different geographic locations. Transfus Med Rev 2004; 18:46-57.
34. Busch MP, Laycock M, Kleinman SH, et al. Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in US blood donors. Retrovirus Epidemiology Donor Study. Blood 1994; 83:1143-8.